Dr. Guangyuan Lou 娄广媛
Chief Physician
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, molecular targeted therapy, and palliative care for solid tumors, including lung, esophageal, breast, and gastrointestinal cancers. Focuses on personalized treatment and overcoming multidrug resistance.
Dr. Lou is a Chief Physician at Zhejiang Cancer Hospital, having joined in 1998 after graduating from China Medical University. Dr. Lou completed advanced studies in pharmacology at Fukuoka University School of Medicine, Japan (2011–2012). Research interests include personalized tumor therapy and multidrug resistance. Dr. Lou has published six articles and participated in one Zhejiang Provincial Health and Medical Research Fund project.
Name order: in Chinese the family name comes first (Lou Guangyuan). Papers usually list the name as Guangyuan Lou or Lou G.
Selected publications
26 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2022 (senior author): Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety. PubMed 36245597
- BMC Cancer, 2022 (senior author): Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. PubMed 35606756
- Transl Lung Cancer Res, 2022 (senior author): Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report. PubMed 35693284
- BMC Cancer, 2022 (senior author): Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma. PubMed 35300627
- Clin Lung Cancer, 2017 (first author): Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma. PubMed 28024928
- Acta Biochim Pol, 2014 (first author): Association between polymorphisms in CHRNA3 and PHACTR2 gene and environment and NSCLC risk in Chinese population. PubMed 25399010
- Zhonghua Yi Xue Za Zhi, 2010 (first author): [Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer]. PubMed 20356491
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion